drugset / Trial / NCT04276727

Menthol In Neuropathy Trial

NCT04276727

Phase 2 Completed 52 enrolled University of Edinburgh NHS Lothian · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Patients will be recruited who have peripheral neuropathy due to chemotherapy. They will be given a blinded treatment of gel containing either menthol (3%) or placebo to be applied for 6 weeks, twice a day. Assessments of pain, neuropathic symptoms and impact on quality of life will be done at baseline, 6 weeks and 12 weeks. Functional magnetic resonance imaging (fMRI) scans will be done at baseline and 6 weeks. Physical activity data will also be collected to be analysed in conjunction with pain assessments.

Timeline

Start
2019-11-04
Primary completion
2022-03-24
Completion
2022-03-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Menthol Small molecule 3 % Topical